Acerus Update
10 juil. 2023 22h39 HE
|
Acerus Pharmaceuticals Corporation
TORONTO, July 10, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company”) announces that, in connection with its creditor protection proceedings under the Companies’ Creditors...
Acerus Update
25 mai 2023 21h55 HE
|
Acerus Pharmaceuticals Corporation
TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- As announced on January 26, 2023, Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) and its subsidiaries were granted creditor protection...
Acerus Announces Commencement of Court-Approved Sale and Investment Solicitation Process
14 mars 2023 07h30 HE
|
Acerus Pharmaceuticals Corporation
TORONTO, March 14, 2023 (GLOBE NEWSWIRE) -- On January 26, 2023, Acerus Pharmaceuticals Corporation and certain of its subsidiaries (collectively, “Acerus”) were granted protection pursuant to an...
Acerus Files For CCAA Protection
26 janv. 2023 10h57 HE
|
Acerus Pharmaceuticals Corporation
TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that the Company and its subsidiaries, Acerus...
Acerus Announces Resignation of Director
26 déc. 2022 07h00 HE
|
Acerus Pharmaceuticals Corporation
TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that Mr. Scott Leckie has resigned from the board...
Acerus Announces New Loan Agreement With First Generation Capital
22 déc. 2022 07h00 HE
|
Acerus Pharmaceuticals Corporation
TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that it and its wholly-owned subsidiary, Acerus...
Acerus Reports Third Quarter 2022 Financial Results
15 nov. 2022 07h30 HE
|
Acerus Pharmaceuticals Corporation
TORONTO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and nine-month...
Acerus Announces Amendment to Promissory Note Due to Former Serenity Shareholders
03 oct. 2022 07h30 HE
|
Acerus Pharmaceuticals Corporation
TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has amended the promissory note (the “Note”)...
Acerus Announces Initiation of Strategic Review
21 sept. 2022 07h30 HE
|
Acerus Pharmaceuticals Corporation
Ernst & Young Orenda Corporate Finance Inc. (“EY”) engaged as independent financial advisors TORONTO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or...
Acerus Announces Resignation of CFO Effective November 20, 2022
23 août 2022 07h30 HE
|
Acerus Pharmaceuticals Corporation
TORONTO, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that Robert Motz has informed the Company of his...